Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Announces Poster Presentation at the 2014 World Transplant Congress
SAN DIEGO, July 28, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, announces that Dr. Lewis W. Teperman, Chief of the Division of Transplant Surgery at NYU Langone Medical
View HTML
Toggle Summary Vital Therapies Reports on Clinical Trial Progress and EU Regulatory Advice
SAN DIEGO , July 9, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is providing this update on the status of its clinical trials and the European Medical Agency's (EMA)
View HTML
Toggle Summary Vital Therapies Announces First Quarter 2014 Financial Results and Provides Operational Update
Vital Therapies Announces First Quarter 2014 Financial Results and Provides Operational Update SAN DIEGO, CA--(Marketwired - May 28, 2014) - Vital Therapies, Inc. ( NASDAQ : VTL ), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today
View HTML
Toggle Summary Vital Therapies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Vital Therapies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, CA--(Marketwired - May 6, 2014) - Vital Therapies, Inc. ( NASDAQ : VTL ), a biotherapeutic company developing a cell-based therapy targeting treatment of all forms of acute liver failure, today
View HTML
Toggle Summary Vital Therapies, Inc. Reaches Midpoint for Enrollment in VTI-208
Vital Therapies, Inc. Reaches Midpoint for Enrollment in VTI-208 SAN DIEGO, CA--(Marketwired - May 1, 2014) - Vital Therapies, Inc. ( NASDAQ : VTL ), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that the 100 th
View HTML
Toggle Summary Vital Therapies Prices Initial Public Offering
Vital Therapies Prices Initial Public Offering Vital Therapies Prices Initial Public Offering SAN DIEGO, CA--(Marketwired - Apr 16, 2014) - Vital Therapies, Inc. ( NASDAQ : VTL ), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today
View HTML
Toggle Summary Vital Therapies, Inc. Enrolls First Subject From European Site in VTI-208
Vital Therapies, Inc. Enrolls First Subject From European Site in VTI-208 SAN DIEGO, CA--(Marketwired - Feb 18, 2014) - Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that it has enrolled the first
View HTML
Toggle Summary Vital Therapies Enrolls First Subject From Australian Site in VTI-208
Vital Therapies Enrolls First Subject From Australian Site in VTI-208 SAN DIEGO, CA--(Marketwired - Dec 2, 2013) - Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that it has enrolled the first subject
View HTML
Toggle Summary Vital Therapies Files Registration Statement With SEC for Proposed Initial Public Offering
Vital Therapies Files Registration Statement With SEC for Proposed Initial Public Offering SAN DIEGO, CA--(Marketwired - Oct 11, 2013) -  Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that it has
View HTML
Toggle Summary Vital Therapies, Inc. Expands Board of Directors
Vital Therapies, Inc. Expands Board of Directors SAN DIEGO, CA--(Marketwired - Sep 20, 2013) - Vital Therapies®, Inc. (VTI), a biopharmaceutical company developing a cell-based therapy targeting the treatment of acute liver failure, today announced election of Jean-Jacques Bienaimé to the
View HTML